BPG is committed to discovery and dissemination of knowledge
Review
Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Sep 15, 2026; 18(9): 123002
Published online Sep 15, 2026. doi: 10.4251/wjgo.123002
Table 4 Gastric cancer evidence and clinical implications
Pathway/biomarker
Evidence in gastric cancer
Potential clinical implication
FDX1Linked to cuproptosis sensitivity, copper-lactylation signaling, and immune infiltration in gastric cancer-related studies[97,121,122,131,132]Candidate marker for cuproptosis susceptibility and rational selection of copper-modulating strategies[97,121,122,131,132]
DLAT/LIAS/LIPT1/DLD (lipoylation-related genes)Altered expression of lipoylation-related genes has been associated with gastric cancer metabolism and prognosis[47,49-50,122]May help define tumors with mitochondrial metabolic dependence and potential vulnerability to cuproptosis induction[31,47,122]
SLC31A1/ATP7A/ATP7B (copper transporters)Copper transporter dysregulation may affect intracellular copper accumulation, angiogenesis, and response to platinum-based therapy[16,52-56]Potential targets to enhance copper-mediated cytotoxicity or overcome chemotherapy resistance[52-56]
AOC1AOC1 down-regulation suppresses AKT signaling, epithelial-mesenchymal transition, proliferation, invasion, and migration in gastric cancer cells[124]Candidate therapeutic and prognostic biomarker linked to tumor growth and metastasis[124]
ITGB1High ITGB1 expression is associated with poor prognosis in diffuse gastric cancer and may reduce sensitivity to copper ionophores[125,126]Potential stratification marker and actionable node for enhancing cuproptosis-based therapy[125,126]
SERPINE1Elevated SERPINE1 expression in gastric adenocarcinoma is associated with proliferation, migration, and immunosuppressive features[128-130]Candidate prognostic and immune-related marker that may guide combination strategies[128-130]


Write to the Help Desk